book cover

Palliative Care Perspectives : Chapter 4: Pain Management : References

1. Good, M. et al., eds. Pain as Human Experience. 1992, University of California Press: Berkeley, p. 1.

2. Portenoy, R. K. and P. Lesage. Management of cancer pain. Lancet 1999; 353(9165): 1695-700.

3. Bonica, J. and J. D. Loeser. Medical evaluation of the patient with pain. In: Bonica J., C. Chapman and W. Fordyce, eds. The Management of Pain. 1990, Lea & Febiger: Philadelphia, pp.563-79.

4. SUPPORT. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). JAMA 1995; 274(20): 1591-8.

5. Won, A. et al. Correlates and management of nonmalignant pain in the nursing home. SAGE Study Group. Systematic assessment of geriatric drug use via epidemiology. J Am Geriatr Soc 1999; 47(8): 936-42.

6. Grossman, S.A. et al. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 1991; 6(2): 53-7.

7. McDowell, I. and C. Newell. Measuring Health:A Guide to Rating Scales and Questionnaires, 2nd ed. 1996, Oxford University Press: New York, pp.355-79.

8. Weissman, D. E. and J. D. Haddox. opioid pseudoaddiction - An iatrogenic syndrome. Pain 1989; 36(3): 363-6.

9. Twycross, R. Pain Relief in Advanced Cancer. 1994, Churchill Livingstone: London, pp. 240, 288, 325, 353, 409-16.

10. Jenkins, C. A. and E. Bruera. Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Palliat Med 1999; 13(3): 183-96.

11. Hudson, N., A. Taha, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112: 1817-22.

12. Hawkey, C. Cox-2 Inhibitors. Lancet 1999; 353: 307-14.

13. Silverstein, F. E. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284(10): 1247-55.

14. Porter, J. and H. Jick. Addiction rare in patients treated with narcotics [letter]. N Engl J Med 1980; 302(2): 123.

15. Joranson, D. E. et al. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283(13): 1710-4.

16. Allan, L. et al. Randomized crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322(7295): 1154-8.

17. Radbruch, L. et al. Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14(2): 111-9.

18. Mercandante, S. The role of morphine glucuronides in cancer pain. Palliat Med 1999; 12: 182-9.

19. Abrahm, J. A Physician's Guide to Pain and Symptom Management in Cancer Patients. 2000, Johns Hopkins University Press: Baltimore, pp. 135-6.

20. Grossman, S. A. et al. Morphine-induced venodilation in humans. Clinical Pharmacol Ther 1999; 60: 554-60.

21. Warner, M.A. et al. Narcotic-induced histamine release: A comparison of morphine, oxymorphone, and fentanyl infusions. J Cardiothorac Vasc Anesth 1991; 5(5): 481-4.

22. Doenicke, A. et al. Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes. Clin Pharmacol Ther 1995; 58: 81-9.

23. Katcher, J. and D. Walsh. opioid-induced itching: Morphine sulfate and hydromorphone hydrochloride. J Pain Symptom Manage 1999; 17(1): 70-2.

24. Broomhead, A. et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997; 14(2): 63-73.

25. Angst, M.S. et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001; 94(1): 63-73.

26. Hanks, G. and N.I. Cherny. opioid analgesic therapy. In: D. Doyle, G. Hanks, et al., eds. The Oxford Textbook of Palliative Medicine. 1998, Oxford University Press: New York, pp.331-5, 338-9.

27. Maddocks, I. et al. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996; 12: 182-9.

28. Bruera, E. et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncology 1998; 6: 3222-9.

29. Mercadante, S. et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol 2001; 19(11): 2898-904.

30. Pereira, J. et al. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001; 22(2): 672-87.

31. Ripamonti, C. et al. Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? J Clin Oncol 1998; 16(10): 3216-21.

32. Southam, M. Transdermal fentanyl therapy: System design, pharmacokinetics and efficacy. Anti-Cancer Drugs 1995; 6(suppl 3): 26-34.

33. Grond, S. et al. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999; 18(3): 174-9.

34. Levy, M.H. Pharmacologic treatment of cancer pain. New Engl J Med 1996; 335(15): 1124-32.

35. Ulens, C., P. Daenens, et al. Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res 1999; 44(3): 568-78.

36. Tremont-Lukats, I.W., C. Megeff, et al. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 2000; 60(5): 1029-52.

37. Hemstreet, B. and M. Lapointe. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther 2001; 23(4): 520-31.

38. Garafalo, E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998; 280: 1831-6.

39. Kishore, A. and L. King. Fast Fact and Concept #49; Gabapentin for neuropathic pain. End of Life Care Education Project. http://www.eperc.mcw.edu/, 2001.

40. Miller, L.J. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother 2001; 35(4): 427-31.

41. Pande, A.C. et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20(4): 467-71.

42. Hanks, G. and N.I. Cherny. opioid analgesic therapy. In: D. Doyle, G. Hanks, et al., eds. The Oxford Textbook of Palliative Medicine. 1998, Oxford University Press: New York, p.340.

43. Farrar, J. et al. Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo controlled trial for treatment of breakthrough pan in cancer patients. J Natl Cancer Inst 1998; 90: 611-6.

44. Chandler, S. Nebulized opioids to treat dyspnea. American Journal of Hospice & Palliative Care 1999; 1999(16): 418-22.

45. Nelson, K. et al. A prospective, within-patient, crossover study of continous intravenous and subcutaneous morphine for chornic cancer pain. J Pain Symptom Manage 1997; 13: 262-7.

46. Portenoy, R.K., ed. Cancer pain management: Update on breakthrough pain. Seminars in Oncology 1997; 24(suppl): 116.

47. Anderson, R. et al. Accuracy in equianalgesic dosing: Conversion dilemmas. J Pain Symptom Manage 2001; 21(5): 397-406.

48. Gordon, D.B. opioid equianalgesic calculations. Journal of Palliative Medicine 1999; 2(2): 209-18.

49. Ripamonti, C. et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences. Ann Oncol 1998; 9(1): 79-83.

50. Lawlor, P., K. Turner, et al. (1997). "Dose ratio between morphine and hydromorphone in patient with cancer pain: a retrospective study." Pain 72(1-2): 79-85.

<<< Previous [ Go Up ]



book cover

Palliative Care Perspectives

James L. Hallenbeck, M.D.

Order hardback from Amazon.com
Order paperback from Amazon.com

Copyright 2003 by Oxford University Press, Inc.

The online version of this book is used with permission of the publisher and author on web sites affiliated with the Inter-Institutional Collaborating Network on End-of-life Care (IICN), sponsored by Growth House, Inc.